Salt Lake City, UT

Utah Kidney Research Institute

Focal Segmental Glomerulosclerosis

Kidney Diseases

Nephrotic Syndrome

Nephrosis

Diabetes Complications

Autosomal Dominant Polycystic Kidney

Obesity

Cardiovascular Diseases

Polycystic Kidney Diseases

Arthrogryposis

CCX140-B

Lixivaptan

Retatrutide

GFB-887

RG-012

ChemoCentryx

Genzyme

Goldfinch Bio

Lilly

Palladio Biosciences

Transplant Genomics

condition

Overweight

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Utah Kidney Research Institute | Salt Lake City, UT

Site insights

Work at this site?

Active trials

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Trial sponsors